Pompidou A, Soubrane C, Cour V, Telvi L, Meunier C, Jacquillat C
Hôpital Saint-Vincent de Paul, Paris, France.
Cancer Detect Prev Suppl. 1987;1:457-62.
Immunomodulatory effect of Isoprinosine are presented in melanoma and HTLV-III/LAV infected patients. Isoprinosine (50 mg/kg) was used as a pulse immunotherapy according to two different schedules: A) 5 days every 15 days and B) 5 days every 15 days for 2 months, then 5 days every 2 months. The patients' immunological profiles were tested before and during the treatment in terms of T-cell subsets, cell number requirement for PHA-induced proliferation, and delayed hypersensitivity reaction to recall antigens. Primary malignant melanoma patients are randomized between surgery alone or associated to isotherapy (schedule A or B). Schedule A, after an initial improvement of surgery-induced immune deficiency, is responsible for an immunodepression, whereas schedule B determines a prolonged restoration in immune responses in melanoma and AIDS related complex or Kaposi sarcoma patients as well. In vitro effects of Isoprinosine on HTLV-III/LAV infection are presented. These data exhibit 1) the need of an immunological follow-up during isotherapy and 2) the immunological benefit of a pulse immunotherapy during acquired immunodeficiencies related to cancer surgery or to HTLV-III/LAV infection in man.
异搏定在黑色素瘤患者及人类嗜T淋巴细胞病毒III型/淋巴腺病相关病毒（HTLV-III/LAV）感染患者中具有免疫调节作用。异搏定（50毫克/千克）根据两种不同方案用作脉冲免疫疗法：A）每15天用药5天；B）每15天用药5天，持续2个月，之后每2个月用药5天。在治疗前及治疗期间，针对患者的T细胞亚群、PHA诱导增殖所需的细胞数量以及对回忆抗原的迟发型超敏反应检测其免疫学特征。原发性恶性黑色素瘤患者被随机分为单纯手术组或联合免疫疗法组（方案A或B）。方案A在初步改善手术引起的免疫缺陷后，会导致免疫抑制，而方案B则能使黑色素瘤、艾滋病相关综合征或卡波西肉瘤患者的免疫反应得到长期恢复。文中还介绍了异搏定对HTLV-III/LAV感染的体外作用。这些数据表明：1）免疫疗法期间需要进行免疫学随访；2）在与癌症手术或人类HTLV-III/LAV感染相关的获得性免疫缺陷期间，脉冲免疫疗法具有免疫学益处。
